Ventilation Parameters Before Extracorporeal Membrane Oxygenator and In-Hospital Mortality in Children

ASAIO Journal ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Angelo Polito ◽  
Elise Dupuis-Lozeron ◽  
Ryan Barbaro ◽  
Peter C. Rimensberger
2021 ◽  
Vol 14 (6) ◽  
Author(s):  
Jeong Hoon Yang ◽  
Ki Hong Choi ◽  
Young-Guk Ko ◽  
Chul-Min Ahn ◽  
Cheol Woong Yu ◽  
...  

Background: In the current era of mechanical circulatory support, limited data are available on prognosis of cardiogenic shock (CS) caused by various diseases. We investigated the characteristics and predictors of in-hospital mortality in Korean patients with CS. Methods: The RESCUE study (Retrospective and Prospective Observational Study to Investigate Clinical Outcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With CS) is a multicenter, retrospective, and prospective registry of patients that presented with CS. Between January 2014 and December 2018, 1247 patients with CS were enrolled from 12 major centers in Korea. The primary outcome was in-hospital mortality. Results: In-hospital mortality rate was 33.6%. The main causes of shock were ischemic heart disease (80.7%), dilated cardiomyopathy (6.1%), myocarditis (3.2%), and nonischemic ventricular arrhythmia (2.5%). Vasopressors were used in 1081 patients (86.7%). The most frequently used vasopressor was dopamine (63.4%) followed by norepinephrine (57.3%). An intraaortic balloon pump was used in 314 patients (25.2%) and extracorporeal membrane oxygenator in 496 patients (39.8%). In multivariable analysis, age ≥70years (odds ratio [OR], 2.73 [95% CI, 1.89–3.94], P <0.001), body mass index <25 kg/m 2 (OR, 1.52 [95% CI, 1.08–2.16], P =0.017), cardiac arrest at presentation (OR, 2.16 [95% CI, 1.44–3.23], P <0.001), vasoactive-inotrope score >80 (OR, 3.55 [95% CI, 2.54–4.95], P <0.001), requiring continuous renal replacement therapy (OR, 4.14 [95% CI, 2.88–5.95], P <0.001), mechanical ventilator (OR, 3.17 [95% CI, 2.16–4.63], P <0.001), intraaortic balloon pump (OR, 1.55 [95% CI, 1.07–2.24], P =0.020), and extracorporeal membrane oxygenator (OR, 1.85 [95% CI, 1.25–2.76], P =0.002) were independent predictors for in-hospital mortality. Conclusions: The in-hospital mortality of patients with CS remains high despite the high utilization of mechanical circulatory support. Age, low body mass index, cardiac arrest at presentation, amount of vasopressor, and advanced organ failure requiring various support devices were poor prognostic factors for in-hospital mortality. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02985008.


1994 ◽  
Vol 33 (9) ◽  
pp. 569-573 ◽  
Author(s):  
Shoichiro DAIMON ◽  
Tomoya UMEDA ◽  
Ichiro Ichiro MICHISHITA ◽  
Harue WAKASUGI ◽  
Akira GENDA ◽  
...  

Author(s):  
R.E. Witt ◽  
M. Singhal ◽  
A.J. Vachharajani

BACKGROUND: The purpose of this study was to compare the outcomes of infants with giant omphalocele (GO) born in two different epochs over two decades at a single institution. Specifically, it examined whether the utilization of selective pulmonary vasodilators and extracorporeal membrane oxygenator (ECMO) in the management of pulmonary hypertension in the second epoch were associated with improved outcomes. METHODS: The medical records of all patients diagnosed with GO at a large children’s hospital from January 1, 1996 to December 31, 2016 were reviewed and divided into two epochs. Patients were classified as having an isolated GO or GO with minor or major associated anomalies. GO was defined as a defect more than or equal to 5 cm in size and/or liver in the sac. RESULTS: During the study period, 59 infants with GO were identified. The duration of invasive mechanical ventilation was significantly shorter among the survivors from the second epoch (p = 0.03), with none greater than seven days. There were no significant differences in the outcomes of survival to NICU discharge and length of stay (LOS) between infants in the two epochs. CONCLUSIONS: Infants with GO who required invasive mechanical ventilation for more than seven days did not survive in the second epoch. Survival did not improve with uses of selective pulmonary vasodilators and ECMO. This information could be shared with families during prenatal and postnatal counselling to facilitate informed decision making regarding goals of care.


2020 ◽  
Author(s):  
Marta Alonso‐Fernandez‐Gatta ◽  
Soraya Merchan‐Gomez ◽  
Miryam Gonzalez‐Cebrian ◽  
Alejandro Diego‐Nieto ◽  
Elisabete Alzola ◽  
...  

ASAIO Journal ◽  
2011 ◽  
Vol 57 (3) ◽  
pp. 158-163 ◽  
Author(s):  
Ruedger Kopp ◽  
Ralf Bensberg ◽  
Jutta Arens ◽  
Ulrich Steinseifer ◽  
Thomas Schmitz-Rode ◽  
...  

2018 ◽  
Vol 39 (3) ◽  
pp. 366-367 ◽  
Author(s):  
Rami Sommerstein ◽  
Tobias M. Merz ◽  
Stephan M. Jakob ◽  
Jukka Takala ◽  
Jonas Marschall

2020 ◽  
pp. 106002802096040
Author(s):  
Abdulrazaq Al-Jazairi ◽  
Shahad Raslan ◽  
Rayd Al-mehizia ◽  
Hani Al Dalaty ◽  
Edward B. De Vol ◽  
...  

Background The use of extracorporeal membrane oxygenator (ECMO) support devices are associated with complications, including bleeding and thrombosis. Unfractionated heparin (UFH) is the gold standard anticoagulant in ECMO patients. Clinically, UFH is monitored through activated clotting time (ACT), activated partial thromboplastin time (aPTT), and anti–factor Xa assay. It is unknown which assay best predicts anticoagulation effects in adults. Objective To assess the correlation of UFH dosing and monitoring using an established protocol. Methods A pilot, prospective cohort, historically controlled study was conducted at a tertiary care hospital. Patients ≥18 years-old who received ECMO on the multifaceted anticoagulation protocol were included and compared with those on the conventional method of anticoagulation. The primary end point was to assess the correlation between UFH dose and different monitoring methods throughout 72 hours using the new protocol guided by ACT and anti–factor Xa assay. Results In each arm, 20 patients were enrolled. The study revealed that anti–factor Xa assay had the largest number of “strong” correlations 11/20 (55%), followed by both aPTT and aPTT ratio 10/20 (50%), and, finally, ACT 2/20 (10%). Concordance between anti–factor Xa assay and the other monitoring parameters in the prospective arm was generally low: 31% with aPTT ratio, 26% with ACT, and 23% with aPTT. Conclusion and Relevance The adaption of a multifaceted anticoagulation protocol using anti–factor Xa assay may provide a better prediction of heparin dosing in adults ECMO patients compared with the conventional ACT-based protocol. Further studies are needed to assess the safety and different monitoring modalities.


Sign in / Sign up

Export Citation Format

Share Document